Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing

Reuters

Aug 19

Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing

Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab $(BOT.AU)$ and balstilimab $(BAL.AU)$ program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer $(CRC)$ studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560419564"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560419564\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560419564?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560419564","market":"fut","top_or_hot":-1,"title":"Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab <a href=\"https://laohu8.com/S/BOT.AU\">$(BOT.AU)$</a> and balstilimab <a href=\"https://laohu8.com/S/BAL.AU\">$(BAL.AU)$</a> program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a> studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&amp;A, allowing for further engagement and clarification.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab <a href=\"https://laohu8.com/S/BOT.AU\">$(BOT.AU)$</a> and balstilimab <a href=\"https://laohu8.com/S/BAL.AU\">$(BAL.AU)$</a> program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a> studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&amp;A, allowing for further engagement and clarification.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉纳斯公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL8zzVK2:1","article_id":"2560419564","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560419564","pubTimestamp":1755603034,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab  and balstilimab  program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer  studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus Inc.在即将举行的虚拟利益相关者简报会上宣布免疫肿瘤学领域的战略进展和关键里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    \n\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab $(BOT.AU)$ and balstilimab $(BAL.AU)$ program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer $(CRC)$ studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}